HOTH Rocket One Inc.
USHealthcareAs of 2026-07-10 15:59
Why HOTH matters now
Rocket One Inc. (HOTH) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.88 with -3.23% on the session and $11.7M in market capitalization; recent performance reads 1-month +78.33% and YTD +8.08%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.7M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -41.8%.
The latest indexable market news headline is "Why Hoth Therapeutics (HOTH) Stock Is Surging After Hours Today" from Benzinga.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.10
P/S
0.00
EV/EBITDA
-1.72
DCF Value
$0.40
FCF Yield
-41.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-165.2%
ROA
-208.9%
ROIC
-277.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.7M | $-0.17 |
| Q4 2025 | $0.00 | $-2.7M | $-0.17 |
| FY 2025 | $0.00 | $-12.5M | $-0.90 |
| Q3 2025 | $0.00 | $-4.1M | $-0.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.58
Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.